Market Overview

UPDATE: Goldman Sachs Group Initiates Coverage on Kythera Biopharmaceuticals with Neutral Rating, $23 PT

Related KYTH
CORRECTION: Kythera Reports FDA Acceptance of ATX-101 NDA, PDUFA Date Set at May 13, 2015
Kythera Reports FDA Acceptance of ATX-101 NDA, PDUFA Date Set at May 13, 2015

In a report published Monday, Goldman Sachs Group initiated coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Neutral rating and $23.00 price target.

Goldman Sachs noted, “We initiate coverage of Kythera Biopharmaceuticals at Neutral with a $23, 12-month price target, implying 4% upside. Kythera's story is driven by ATX-101, a first-in-class injectable product for localized fat reduction that we believe holds both a high likelihood of achieving FDA approval and significant sales potential. The product is supported by strong clinical data, addresses an unmet aesthetic need for a potentially large patient population, and presents a compelling argument for quick physician adoption. With shares up sharply since IPO (38% vs. S&P -2%), we believe the strong fundamentals are currently reflected in shares, driving our Neutral rating.”

Kythera Biopharmaceuticals closed on Friday at $22.11.

Latest Ratings for KYTH

DateFirmActionFromTo
Nov 2013Empire Asset ManagementInitiates Coverage onSell
Oct 2013Bank of AmericaInitiates Coverage onBuy
Sep 2013Goldman SachsAssumesNeutral

View More Analyst Ratings for KYTH
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Initiation Analyst Ratings

 

Related Articles (KYTH)

Around the Web, We're Loving...

Get Benzinga's Newsletters